Angiotensin 2 Receptor Blocker [EPC]

This page covers all Angiotensin 2 Receptor Blocker [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Type-1 angiotensin II receptor, Type-2 angiotensin II receptor, AT1 receptor.

Targets

Type-1 angiotensin II receptor · Type-2 angiotensin II receptor · AT1 receptor

Marketed (8)

• Diovan · Novartis · Metabolic · 447
  Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.
• Micardis · Boehringer Ingelheim · Metabolic
  Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.
• Avapro · Sanofi · Metabolic
• Atacand · ANI Pharmaceuticals · Metabolic
  Atacand blocks the action of angiotensin II, a hormone that constricts blood vessels, to lower blood pressure and improve heart function.
• Avapro · Sanofi · Metabolic
  Avapro works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.
• Teveten · AbbVie · Metabolic
• Edarbi · Arbor Pharms Ireland · Cardiovascular
  Azilsartan blocks angiotensin II's vasoconstrictor and aldosterone-secreting effects by selectively binding to the AT1 receptor.
• Cozaar · Merck & Co. · Metabolic
  Cozaar works by blocking the action of angiotensin II on its receptor, which helps to relax blood vessels and lower blood pressure.

Patent intelligence

• angiotensin 2 receptor blocker patent landscape — aggregated cliff calendar, attackable patents, originator estates